體外診斷藥物(IVD)趨勢與市場最新資訊: 2023年11月
市場調查報告書
商品編碼
1376525

體外診斷藥物(IVD)趨勢與市場最新資訊: 2023年11月

In Vitro Diagnostic (IVD) Trends and Market Update: November 2023

出版日期: | 出版商: Kalorama Information | 英文 40 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

體外診斷 (IVD) 測試正在恢復正常運行,並繼續成為醫療實踐的驅動力。IVD 測試正在從幫助醫生診斷疾病轉向為醫生提供有關精準醫療等治療的有價值的資訊。儘管 COVID-19 檢測持續下降,但它仍然是 2023 年總收入的驅動力。

市場中有幾個不斷增長的細分市場正在引起業界的關注。其中包括 POC、次世代定序 (NGS)、癌症檢測和伴隨診斷技術。免疫化學、質譜、基因檢測和分子診斷也是市場關注的領域,預計將成為 IVD 未來的重要組成部分。

本報告審視了全球體外診斷藥物 (IVD) 市場,並提供了市場概況以及主要參與者的市場進入趨勢和新機會。

目錄

第一章 全球 IVD 市場 - 2023 年 10 月最新訊息

  • IVD市場需求與成長
  • COVID-19診斷市場
  • COVID-19 對細分市場的影響

第二章 產品趨勢及新進展

  • 精選新產品 - 2023 年第三季 - 核心 IVD 產品發布、開發和趨勢
  • 臨床化學
  • 流式細胞儀
  • 免疫測定法
  • 質譜
  • 分子
  • 個性化醫療
  • POC
  • 測序
  • COVID-19 的一些進展 - 2023 年第 3 季度
  • 抗原/抗體
  • 分子

第三章 主要IVD市場參與者業績

  • 有關精心挑選的競爭領導者的最新信息
  • 第三季併購活動
  • Abbott Laboratories
  • Becton Dickinson and Co
  • bioMerieux
  • Danaher Corporation
  • Hologic, Inc.
  • QuidelOrtho Corporation
  • Roche Diagnostic
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific

第四章 新機遇

  • 多重測試
  • 下一代定序
  • 人工智慧的未來趨勢
  • 顛覆性技術
簡介目錄
Product Code: 23-046

In vitro diagnostic (IVD) testing is getting back to regular business and continues to be a driving force in the practice of medicine. It has gone from helping the physician to diagnose illness to providing the physician with invaluable information on treatments such as precision medicine. COVID-19 testing continues to decline but is still a factor in total revenues for 2023. New products, changes in global health spending, regulatory changes in major markets and disease trends are among the factors that produce a constantly changing market picture but one that remains resilient.

“IVD Trends and Market Update: November 2023” by Kalorama Information is the most up-to-date resource on these and other key market trends. Diagnostic test products have never been more important. This report is an update of the market for in vitro diagnostics products from Kalorama's analysts to reflect the latest information as of Q3 2023 with a publication date of November 2023.

There are some growing segments in the market that have attracted industry attention. Among these are Point-of-Care, next-generation sequencing (NGS), cancer testing, and companion diagnostics technologies. Immunochemistry, mass spectrometry. Gene testing and molecular diagnostics are also segments of great market interest, anticipated to be a big part of the future of IVD.

Trends highlighted throughout Q3 2023 include:

  • Multiplex testing is proliferating
  • Continued interest in adopting AI technologies

Kalorama Information maintains its unwavering dedication to examining the IVD market and its dynamically evolving landscape. The company's excellence in market analysis is attributed to the extensive expertise of its authors and the market research firm's resolute commitment to providing the most precise and up-to-date data.

In “IVD Trends and Market Update: November 2023”, you'll discover out:

  • What's Driving Growth in the IVD Market in Q3 and the last half of 2023?
  • What Major Trends are Affecting the Market in Q3 and the last half of 2023?
  • How Has COVID-19 Impacted and Continued to Impact the Market in Q3 and the last half of 2023?
  • What Product Trends and New Developments Will Shape the IVD Market in the last half of 2023?

Table of Contents

Chapter 1: Worldwide IVD Market - October 2023 Update

  • IVD Market Demand and Growth
  • Figure 1-1: Q3 Segment Performance Commentary, 2023
    • Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2023 ($ million) (Clinical Chemistry; Immunoassays - non isotopic [Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab]; Hematology - Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Microbiology - Mass Spectrometry; Coagulation [PT/INR]; Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
    • Figure 1-2: IVD Segment Performance, Q1 2023 - Q4 2023e ($MN)
    • Figure 1-3: IVD Segment Performance (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Total Market Value, 2023 ($MN) Estimated
  • COVID-19 Diagnostic Markets
    • Table 1-2: COVID-19 Product Sales, by Segment (Immunoassay [Antigen, Serology], Molecular, Rapid [POC Professional, POC At-Home]), 2023 ($ millions)
  • Effect of COVID-19 on Market Segments
    • Table 1-3: IVD Market (excluding and with COVID-19), 2023 ($ millions)
    • Figure 1-4: IVD Market Distribution, by Segment (COVID-19 Assays and Instruments, IVD Market excluding COVID-19 Assays and Instruments), 2023 (%)
    • Figure 1-5: IVD Market by COVID-19 and non-COVID Markets, Quarterly Performance, 2023 Estimated ($ millions)
    • Table 1-4: Global In Vitro Diagnostic Market, by Segment (Clinical Chemistry; Immunoassays - non isotopic [Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab]; Hematology - Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Coagulation [PT/INR]; Histology/cytology; d-dimer; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; POC, OTC diabetes; POC, OTC other; POC, professional/hospital), YoY Growth 2022-2023 (%)
    • Figure 1-6: Global In Vitro Diagnostic Market, by Segment (Clinical Chemistry; Immunoassays - non isotopic [Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab]; Hematology - Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Coagulation [PT/INR]; Histology/cytology; d-dimer; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; POC, OTC diabetes; POC, OTC other; POC, professional/hospital), YoY Growth 2022-2023 (%)

Chapter 2: Product Trends and New Developments

  • Selected New - Q3 2023 - Core IVD Product Launches, Developments and Trends
  • Clinical Chemistry
  • Flow Cytometry
  • Immunoassay
  • Mass Spectrometry
  • Molecular
  • Personalized Medicine
  • POC
  • Sequencing
  • Selected COVID-19 Developments - Q3 2023
    • Figure 2-1: COVID-19 Test Market, by Type (Antigen, Molecular, Serology, Rapid), Q1-Q4 2023 ($ millions)
  • Antigen/Antibody
  • Molecular

Chapter 3: Top IVD Market Participant Results

  • Selected Competitive Leader Updates
    • Figure 3-1: IVD Segment Growth, by Leading Competitors (Abbott Diagnostics, Becton Dickinson, bioMérieux, Danaher, Exact Sciences, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific), Change in Sales, 2022-2023 (%)
    • Figure 3-2: Changes in Market Distribution for IVD Sales, 2020-2023 - Roche and Abbott Battle for #1 Spot
    • Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2020-2023 ($ millions)
  • Q3 M&A Activity
    • Table 3-1: Q3 2023 Merger and Acquisition Activity
  • Abbott Laboratories
    • Table 3-2: Abbott Corporate Summary
  • Becton Dickinson and Co
    • Table 3-3: Becton Dickinson Corporate Summary
  • bioMérieux SA
    • Table 3-4: bioMérieux Corporate Summary
  • Danaher Corporation
    • Table 3-5: Danaher Corporation Summary
  • Hologic, Inc.
    • Table 3-6: Hologic Corporate Summary
  • QuidelOrtho Corporation
    • Table 3-7: QuidelOrtho Corporate Summary
  • Roche Diagnostic
    • Table 3-8: Roche Diagnostic Corporate Summary
  • Siemens Healthineers
    • Table 3-9: Siemens Healthineers Corporate Summary
  • Sysmex Corporation
    • Table 3-10: Sysmex Corporate Summary
  • Thermo Fisher Scientific
    • Table 3-11: Thermo Fisher Scientific Corporate Summary

Chapter 4: New Opportunities

  • Multiplex Testing
  • Next-Generation Sequencing
  • Artificial Intelligence Future Trends
  • Disruptive Technologies